Harmony Biosciences Q2 2024 Adj. EPS $1.05 Beats $(0.06) Estimate, Sales $172.814M Miss $173.098M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences (NASDAQ:HRMY) reported Q2 2024 adjusted EPS of $1.05, significantly beating the $(0.06) estimate, and a 38.16% increase from last year. However, sales of $172.814M slightly missed the $173.098M estimate, though they were up 28.76% from the previous year.
August 06, 2024 | 11:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences reported Q2 2024 adjusted EPS of $1.05, beating the $(0.06) estimate by a significant margin, and a 38.16% increase from last year. Sales of $172.814M slightly missed the $173.098M estimate, though they were up 28.76% from the previous year.
The significant beat on EPS, despite the slight miss on sales, is likely to have a positive short-term impact on HRMY's stock price. The substantial year-over-year growth in both EPS and sales further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100